Compare Cytokinetics Inc (CYTK) vs Simon Property Group Inc (SPG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Simon Property Group Inc — how do they compare? Cytokinetics Inc trades at $62.91 (market cap $8.62B), while Simon Property Group Inc trades at $199.42 (market cap $64.59B). The key difference: Simon Property Group Inc is far larger — about 7.5× Cytokinetics Inc's market cap, and Simon Property Group Inc pays a 4.46% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Simon Property Group Inc for 99 Days on average.
| CYTK | SPG | |
|---|---|---|
Market Cap | $8.62B | $64.59B |
Volume | 2,594,626 | 1,093,907 |
Sector | Health | Real Estate |
52-Week High | $87.26 | $236.70 |
52-Week Low | $54.76 | $173.35 |
Typical Hold Time | 19 Days | 99 Days |
Enterprise Value | $8.72B | $93.03B |
Dividend Yield | — | 4.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $62.91, up 2.93% with bearish technical signals despite strong analyst support. The company shows promising drug development with positive Phase 3 results for aficamten in HCM treatment, though fundamentals remain challenged with a P/S ratio of 114 and negative profit margins. Recent executive stock sales and high cash burn from operations highlight ongoing financial pressures despite growing revenue potential from new drug launches.
The outlook balances significant upside potential from analyst price targets averaging $112.60 against substantial execution risks. While clinical successes position CYTK for growth in cardiovascular treatments, persistent losses and high valuation metrics require careful risk assessment. The stock offers speculative growth opportunity but demands close monitoring of commercialization progress and path to profitability.
SPG trades at $199.42, up 0.93% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong revenue growth to $6.36B in 2025 and a net income margin of 66.57%, though Q2 2026 EPS missed expectations. Recent news highlights leasing demand strength and a new media network launch, while analyst consensus is a $222.90 price target with 42% buy ratings.
Outlook is mixed: fundamentals are robust with high profitability and dividend yield, but technical weakness and net cash outflows pose risks. Investors may find value in the discounted valuation relative to targets, though sensitivity to interest rates and debt maturities requires caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Simon Property Group Inc
Simon Property Group is the second- largest real estate investment trust in the United States. Its portfolio includes an interest in 207 properties: 119 traditional malls, 69 premium outlets, 14 Mills centers (a combination of a traditional mall, outlet center, and big-box retailers), six lifestyle centers, and five other retail properties. Simon's portfolio averaged $693 in sales per square foot over the 12 months prior to the pandemic. The company also owns a 21% interest in Klepierre, a European retail company with investments in shopping centers in 16 countries, and joint venture interests in 33 premium outlets across 11 countries.
Read more on SPG →
